Drug Search Results
More Filters [+]

BL-1040

Alternative Names: bl-1040, bl1040, bl 1040
Latest Update: 2012-02-03
Latest Update Note: Clinical Trial Update

Product Description

a novel myocardial implant for the treatment of acute myocardial infarction (MI). BL-1040 represents a breakthrough approach to supporting cardiac tissue damaged as a result of acute myocardial infarction (MI), improving cardiac function and survival. The novel myocardial implant is a resorbable liquid polymer that is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle. (Sourced from: https://ir.biolinerx.com/news-releases/news-release-details/biolinerxs-bl-1040-named-one-10-most-promising-cardiovascular)

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioLineRx
Company Location: MODI-IN L3 7177871
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BL-1040

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Stroke|Heart Rupture|Atrioventricular Block|Heart Block|Heart Failure, Chronic|Cardiac Arrhythmias|Kidney Diseases|Heart Failure, Diastolic|Heart Failure, Systolic|Bradycardia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00557531

P2

Unknown status

Stroke|Heart Block|Heart Failure, Chronic|Heart Rupture|Atrioventricular Block|Kidney Diseases|Cardiac Arrhythmias|Heart Failure, Diastolic|Bradycardia|Heart Failure, Systolic

2010-01-01

Recent News Events

Date

Type

Title